Operating cash flow CAGR uses reported cash from operations before capital expenditures.
Over the past 12 months, Operating Cash Flow CAGR is N/A.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Operating cash flow CAGR measures the compound annual growth rate of the cash BioCryst Pharmaceuticals, Inc. generates from its core business operations, before capital expenditures, computed from rolling-twelve-month cash-flow statement history.
BioCryst Pharmaceuticals, Inc. (BCRX)
Operating Cash Flow growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Reported quarterly operating cash flow; no daily interpolation. Q2 FY2026 (2026-06-30): $104.34M.
FMP quote market capitalization / four-quarter operating cash flow Quote observation: 2026-10-06T13:45:44.993Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
| Year | Start OCF | End OCF | Change | % Change |
|---|---|---|---|---|
| 2025 | −$52.02M | $329.88M | +$381.90M | N/A |
| 2024 | −$95.14M | −$52.02M | +$43.12M | N/A |
| 2023 | −$161.85M | −$95.14M | +$66.71M | N/A |
| 2022 | −$142.16M | −$161.85M | −$19.69M | N/A |
| 2021 | −$137.22M | −$142.16M | −$4.94M | N/A |
| 2020 | −$89.58M | −$137.22M | −$47.63M | N/A |
| 2019 | −$92.56M | −$89.58M | +$2.98M | N/A |
| 2018 | −$41.14M | −$92.56M | −$51.42M | N/A |
| 2017 | −$53.44M | −$41.14M | +$12.29M | N/A |
| 2016 | −$13.12M | −$53.44M | −$40.32M | N/A |
| 2015 | −$38.55M | −$13.12M | +$25.43M | N/A |
| 2014 | −$26.53M | −$38.55M | −$12.02M | N/A |
| 2013 | −$37.40M | −$26.53M | +$10.87M | N/A |
| 2012 | −$32.25M | −$37.40M | −$5.15M | N/A |
| 2011 | −$28.55M | −$32.25M | −$3.70M | N/A |
| 2010 | −$16.22M | −$28.55M | −$12.34M | N/A |
| 2009 | −$20.87M | −$16.22M | +$4.66M | N/A |
| 2008 | −$25.00M | −$20.87M | +$4.12M | N/A |
| 2007 | −$15.21M | −$25.00M | −$9.79M | N/A |
| 2006 | −$23.35M | −$15.21M | +$8.13M | N/A |
| 2005 | −$18.15M | −$23.35M | −$5.19M | N/A |
| 2004 | −$11.20M | −$18.15M | −$6.96M | N/A |
| 2003 | −$16.36M | −$11.20M | +$5.17M | N/A |
| 2002 | −$10.16M | −$16.36M | −$6.21M | N/A |
| 2001 | −$3.18M | −$10.16M | −$6.98M | N/A |
| 2000 | −$4.90M | −$3.18M | +$1.72M | N/A |
| 1999 | −$4.20M | −$4.90M | −$700.00K | N/A |
| 1998 | −$10.30M | −$4.20M | +$6.10M | N/A |
| 1997 | −$6.80M | −$10.30M | −$3.50M | N/A |
| Period | Period End | Value | QoQ Growth | YoY Growth |
|---|---|---|---|---|
| Q2 FY2026 | 2026-06-30 | $104.34M | N/A | +152.6% |
| Q1 FY2026 | 2026-03-31 | -$62.14M | N/A | -125.8% |
| Q4 FY2025 | 2025-12-31 | $276.04M | +563.2% | N/A |
| Q3 FY2025 | 2025-09-30 | $41.62M | +0.8% | +404.8% |
| Q2 FY2025 | 2025-06-30 | $41.30M | N/A | N/A |
| Q1 FY2025 | 2025-03-31 | -$27.52M | -427.9% |
| +48.7% |
| Q4 FY2024 | 2024-12-31 | -$5.21M | N/A | +41.5% |
| Q3 FY2024 | 2024-09-30 | $8.24M | N/A | N/A |
| Q2 FY2024 | 2024-06-30 | -$1.37M | +97.5% | +92.7% |
| Q1 FY2024 | 2024-03-31 | -$53.68M | -502.0% | -13.0% |
| Q4 FY2023 | 2023-12-31 | -$8.92M | +55.2% | +62.6% |
| Q3 FY2023 | 2023-09-30 | -$19.90M | -5.8% | +38.7% |
| Q2 FY2023 | 2023-06-30 | -$18.81M | +60.4% | +32.2% |
| Q1 FY2023 | 2023-03-31 | -$47.51M | -99.2% | +38.9% |
| Q4 FY2022 | 2022-12-31 | -$23.85M | +26.5% | +26.5% |
| Q3 FY2022 | 2022-09-30 | -$32.44M | -16.9% | -39.4% |
QoQ Growth compares the previous fiscal quarter; YoY Growth compares the same fiscal quarter in the prior fiscal year. Missing or ambiguous fiscal periods render N/A.
